Literature DB >> 1652369

The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.

H de Thé1, C Lavau, A Marchio, C Chomienne, L Degos, A Dejean.   

Abstract

We have previously shown that the t(15;17) translocation specifically associated with acute promyelocytic leukemia (APL) fuses the retinoic acid receptor alpha (RAR alpha) locus to an as yet unknown gene, initially called myl and now renamed PML. We report here that this gene product contains a novel zinc finger motif common to several DNA-binding proteins. The PML-RAR alpha mRNA encodes a predicted 106 kd chimeric protein containing most of the PML sequences fused to a large part of RAR alpha, including its DNA- and hormone-binding domains. In transient expression assays, the hybrid protein exhibits altered transactivating properties if compared with the wild-type RAR alpha progenitor. Identical PML-RAR alpha fusion points are found in several patients. These observations suggest that in APL, the t(15;17) translocation generates an RAR mutant that could contribute to leukemogenesis through interference with promyelocytic differentiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652369     DOI: 10.1016/0092-8674(91)90113-d

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  349 in total

1.  Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation.

Authors:  P Tamayo; D Slonim; J Mesirov; Q Zhu; S Kitareewan; E Dmitrovsky; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.

Authors:  R D Everett; W C Earnshaw; J Findlay; P Lomonte
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

3.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

5.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

6.  Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein.

Authors:  S Tsuzuki; M Towatari; H Saito; T Enver
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation.

Authors:  Manuel Rosa-Calatrava; Francine Puvion-Dutilleul; Pierre Lutz; Dominique Dreyer; Hugues de Thé; Bruno Chatton; Claude Kedinger
Journal:  EMBO Rep       Date:  2003-10       Impact factor: 8.807

Review 8.  Arsenic trioxide: insights into its evolution to an anticancer agent.

Authors:  Maneka Hoonjan; Vaibhav Jadhav; Purvi Bhatt
Journal:  J Biol Inorg Chem       Date:  2018-02-02       Impact factor: 3.358

9.  C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.

Authors:  Estelle Duprez; Katharina Wagner; Heike Koch; Daniel G Tenen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

10.  Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+ BM cells.

Authors:  D R van Bockstaele; M Lenjou; H W Snoeck; F Lardon; P Stryckmans; M E Peetermans
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.